Article Type
Changed
Mon, 09/10/2018 - 16:25
Display Headline
Update on Wegener granulomatosis
Article PDF
Author and Disclosure Information

Carol A. Langford, MD, MHS
Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: Carol Langford, MD, MHS, Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

No therapeutic agents are specifically approved for the treatment of Wegener granulomatosis. All references to a commercial product constitute an unlabeled use.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.

Issue
Cleveland Clinic Journal of Medicine - 72(8)
Publications
Topics
Page Number
689-690, 693-697
Sections
Author and Disclosure Information

Carol A. Langford, MD, MHS
Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: Carol Langford, MD, MHS, Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

No therapeutic agents are specifically approved for the treatment of Wegener granulomatosis. All references to a commercial product constitute an unlabeled use.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.

Author and Disclosure Information

Carol A. Langford, MD, MHS
Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

Address: Carol Langford, MD, MHS, Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, A50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

No therapeutic agents are specifically approved for the treatment of Wegener granulomatosis. All references to a commercial product constitute an unlabeled use.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic Foundation. They are approved by the author but are not peer-reviewed.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(8)
Issue
Cleveland Clinic Journal of Medicine - 72(8)
Page Number
689-690, 693-697
Page Number
689-690, 693-697
Publications
Publications
Topics
Article Type
Display Headline
Update on Wegener granulomatosis
Display Headline
Update on Wegener granulomatosis
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media